Prevalence of co-existent COVID-19-associated pulmonary aspergillosis (CAPA) and its impact on early mortality in patients with COVID-19-associated pulmonary mucormycosis (CAPM).
Valliappan MuthuRitesh AgarwalShivaprakash Mandya RudramurthyDeepak ThangarajuManoj Radhakishan ShevkaniAtul K PatelPrakash Srinivas ShastriAshwini TayadeSudhir BhandariVishwanath GellaJayanthi SavioSurabhi MadanVinaykumar HallurVenkata Nagarjuna MaturuArjun SrinivasanNandini SethuramanRaminder Pal Singh SibiaSanjay PujariRavindra MehtaTanu SinghalPuneet SaxenaVarsha GuptaVasant NagvekarParikshit PrayagDharmesh PatelImmaculata XessPratik SavajInderpaul Singh SehgalNaresh PandaGayathri Devi RajagopalRiya Sandeep ParwaniKamlesh PatelAnuradha DeshmukhAruna VyasRaghava Rao GandraSrinivas Kishore SistlaPriyadarshini A PadakiDharshni RamarManoj Kumar PanigrahiSaurav SarkarBharani RachagullaPattabhiraman VallandaramamKrishna Prabha PremachandranSunil PawarPiyush GugalePradeep HosamaniSunil Narayan DuttSatish NairHariprasad KalpakkamSanjiv BadhwarKiran Kumar KompellaNidhi SinglaMilind NavlakheAmrita P PrayagGagandeep SinghPoorvesh DhakechaArunaloke ChakrabartiPublished in: Mycoses (2024)
Coinfection of CAPA and CAPM was not uncommon in our CAPM patients and portends a worse prognosis. Prospective studies from different countries are required to know the impact of mixed mould infection.